Why I get to say this

For sixteen years, VRF has sat between academic labs, patient communities, non-profits, biotech and big pharma. We have run a network of biobanks, followed the drug pipeline year after year, worked with investigators and companies, built patient programs, and more recently gone rather deeply into AI and digital health. We have also answered emails from people who quite reasonably want to know why none of this works the way the brochures suggest.

I happened to spend most of those years close enough to all sides to see how differently the same decision looks depending on where you sit. That does not make me neutral, omniscient or especially wise. It just means I have watched the same machine from several doors.

I have been circling parts of this argument for years. In The Vitiligo Paradox, I pointed out that NIH awards with “vitiligo” in the title came to about $22 million over forty years. A single approved dermatology product now sells, in one year, for many times that total, even though vitiligo is only part of its label. I did not call that exploitation. I called it a system.

I had never put the whole argument in one place. Probably because the truth is rarely simple, rarely pleasant, and almost never available in a neat paragraph between two meetings. Getting to the bottom of things takes time, context and a willingness to sit with answers that are less satisfying than the question. Not exactly the dominant habits of our age.

Everything around us is optimized for the short term: quarterly results, grant cycles, insurance budgets, election cycles, publication metrics, clicks, likes, and the increasingly familiar human demand of “why can’t I get what I want right now?” Patients are not outside this system. Neither am I. The proof is rather obvious: very few people will spend an extra five minutes reading a serious answer to a question they may have been asking for years.

And even if everyone involved is operating at the limit of their intelligence and good intentions, the result is still produced by a larger equation running on a different set of rules. Optimizing each part does not necessarily optimize the whole.

The villain we want

The easy answer: Big Pharma is the villain. Somewhere in a glass tower sits an executive who already has the cure and withholds it because a chronic treatment is better business. That story is almost always wrong. Not because companies are saints. Because that is not how the machine actually decides.

And not only in vitiligo. Spend fifteen minutes on YouTube and you can find the same plot for cancer, diabetes, Alzheimer’s, HIV, psoriasis and whatever else the algorithm has decided you should be angry about today. The cure exists. They are hiding it. Watch until the end and don’t forget to subscribe. It works because it is simple, and because it gives us something reality usually refuses to provide: somebody to blame.

Pharmaceutical companies do not routinely hide effective therapies. They are not charities built to eliminate human suffering. They are businesses. They develop medicines inside a machine made of capital, competition, patents, regulation, reimbursement, quarterly expectations and shareholders. That is not an accusation. It is a description.

A drug can be scientifically fascinating and commercially hopeless. Another can be only moderately innovative but fit an existing market, regulatory pathway and reimbursement model. The second one usually gets built.

Early bets on unknowns

A molecule does not simply “work” and then march toward patients. Its fate is decided, then re-decided. Development can take ten or fifteen years, yet some of the most consequential decisions happen early, when almost everything that matters is still unknown.

Is the biology strong enough? Can anyone measure the effect? Will there still be a market in ten years? Will insurers pay? Can it be made at a sensible cost? How long will the patent survive? Will somebody else get there first? Would the same billion dollars make more sense somewhere else?

Nobody knows. So they bet — on the outcome of another bet, in a casino that hasn’t been built yet. Often the bet is wrong. A potentially excellent therapy dies. A mediocre one survives. And every now and then, something brilliant in mice becomes an extremely expensive way of producing very sophisticated disappointment.

Human biology is not an engineering diagram either. The immune system has spent hundreds of millions of years becoming annoyingly resistant to simple solutions. Push one pathway down and another may compensate. Suppress hard enough and toxicity appears. Target too narrowly and efficacy disappears. Elegant in theory. Useless in a patient.

A dropped program does not prove the molecule was bad. It also does not prove somebody buried a cure. Scientific promise was only one variable. By the time anyone knows whether the original decision was right, the people who made it have often moved on, and the molecule may have spent years in a freezer.

Scientists live in systems too

Scientists need grants, publications, tenure, citations, students and, sometimes, investors. A researcher can care deeply about patients and still choose the project most likely to get funded. That does not make the scientist corrupt. It makes the scientist human.

Last year, in Who Gets to Do Vitiligo Science?, I followed the money. Most NIH vitiligo funding went to established US medical schools. Established investigators won more grants. More grants produced more papers. More papers built reputation. Reputation improved the odds of the next grant. It did not need to be rigged. The system reinforced itself.

Everyone selects for what their own system rewards.

Everyone is optimizing. Just not for the same thing.

Academia selects for what can be funded and published. Biotech selects for what will attract the next round, a partner or an acquirer. Pharma selects for assets that can survive scientific, regulatory, manufacturing and commercial risk. Insurers select for cost control within their planning horizon. Hospitals select for a balanced budget. Physicians select partly for evidence and partly for whatever has a reasonable chance of surviving the paperwork.

Patients select for something much simpler: getting better without reorganizing their entire life around a disease. They then meet the final product of all these optimizations and quite reasonably ask: Why was nobody optimizing for me?

Banality of incentives

Big failures do not require big villains. They can be assembled from ordinary decisions, made by ordinary people, responding to ordinary incentives. A portfolio committee drops a molecule. A payer requires failure on two cheaper drugs first. A physician avoids a treatment because prior authorization takes too long. A researcher chooses the question most likely to get funded. A patient gives up after the third denial.

Each decision makes sense locally. Together, they can make very little sense at all.

Hannah Arendt wrote about the banality of evil. What we deal with much more often in healthcare is the banality of incentives. A formulary committee is not a moral monster, and calling it one misses the point. Sometimes everyone behaves rationally and the result is still irrational. Healthcare simply makes that unusually expensive.

None of this is particularly new. Economists, sociologists and systems thinkers have spent decades showing how sensible individual decisions can produce remarkably stupid collective outcomes. Thomas Schelling wrote about the gap between individual motives and aggregate behavior. Herbert Simon reminded us that people make decisions with limited information. Donella Meadows spent a career explaining how feedback loops and system structures can turn good intentions into bad outcomes. Healthcare simply gives us an unusually expensive demonstration.

What this looks like in vitiligo

We increasingly talk about treating active vitiligo earlier. That sounds obvious. Yet the system often rewards almost the opposite.

Try an older treatment first. Wait. Document failure. Meet the coverage criteria. Complete prior authorization. Wait again. Appeal. Maybe appeal again. By the time the patient reaches the treatment that might have worked better earlier, the disease may have progressed.

Nobody designed this sequence to make vitiligo worse. The dermatologist wants to help. The insurer has a formulary. The employer wants premiums contained. The pharmacy benefit manager negotiates rebates. The manufacturer sits across that table, trading price concessions for position. The regulator wants evidence.

Put them together and a child can fail older therapies before reaching something that might have been more useful at the beginning. Every move makes sense inside its own box. None of those boxes is the child’s year. The delay is not a secret plan. It is also not an accident. It is what the bargain produces when the person who waits is not in the room.

Part of the problem is time. The value of early intervention may accumulate over years. Most budgets are counted over much shorter periods. This is one reason I have become skeptical of the word “barriers.” A barrier sounds like a wall somebody built. What we actually have is a web of incentives that generates friction, and friction is harder to fight because nobody owns it.

Nobody in particular set the price. Everybody did.

There are legitimate criticisms of drug prices, and there has been genuinely ugly behavior in this industry. But the number a patient experiences is not created by one hand. Someone sets the list price. Then manufacturers, insurers, pharmacy benefit managers, employers, wholesalers, pharmacies, hospitals and government programs all do what their systems reward: discounts, rebates, formularies, copays, deductibles and restrictions. The patient sees a number at the end and assumes somebody invented it in a room. Often, the room is the system.

There is a further twist. A patient can spend the morning fighting a prior authorization, then check a retirement account that holds an index fund. That fund owns the insurer who delayed the cream and the manufacturer who priced it. Nobody plotted this. It is just how ordinary money is stored. The victim and the shareholder can be the same person. That does not make the denial less real. It means the conflict is inside the same life.

And the watchdog has to eat too

The media is supposed to stand outside and ask awkward questions. It has incentives of its own. Speed, access, clicks, outrage and the need for a clean story all shape what gets covered. A complicated system with no obvious villain is hard to sell. “They buried the cure” is much easier. The patient asking whether reimbursement, funding, commercial strategy and personal expectations might all be interacting over a decade is not ideal for a sixty-second segment.

This does not require corruption. Journalists need sources. Meanwhile, readers complain that journalism is shallow while rewarding the shallow version with their attention. Even the watchdog has to eat. That includes us.

Aspirations versus constraints

Every institution tells the story of its highest purpose. Pharma transforms lives. Universities advance knowledge. Insurers improve health. Hospitals put patients first. Advocacy organizations empower communities. Our own website says VRF has only one incentive. I’d like to believe it. I also know that we need donors, partners and grants like everyone else.

None of this necessarily means anybody is lying. Institutions describe themselves through their aspirations. People experience them through their constraints. That gap is where disappointment lives.

I know plenty of people inside pharmaceutical companies who genuinely believe they are making patients’ lives better. Most probably are. That does not suspend the economics around them. Good intentions are one input, not an exemption. The same applies to the rest of us.

So what?

None of this is an argument for shrugging. If the problem is mostly structural, outrage alone will not fix it.

In 1975, the National Vitiligo Control Act was introduced in Congress and died in committee. Fifty years later, the culture is far louder. World Vitiligo Day reaches tens of millions. State coverage fights get hearings. Some even move. Most do not become law. The federal rulebook has barely moved. Advocacy changes what people are willing to say out loud. That matters. It does not, on its own, rewrite the incentives. That takes evidence, money and someone in the room when the rules get written.

That is also why VRF exists in the peculiar shape it does: a bridge between academia, industry and the patient community. A bridge is useful only if it does not belong entirely to either bank. Vitiligo News turned fifteen this month. Roughly a third of its 25,000 readers are researchers and physicians. Another third are patients, families and advocates. The rest remain a mystery. I call them dark matter.

Sometimes somebody needs to ask an awkward question about a shelved drug, an abandoned study, or a treatment that seems strangely difficult to obtain. The question should come before the accusation.

Misconduct is real. Companies have manipulated markets, hidden information, distorted publications, paid kickbacks and broken laws. Those cases deserve scrutiny without euphemism. Structural explanations should never become moral detergent. Sometimes somebody really does cheat. But systems before conspiracy is usually a better place to start.

The view from inside the machinery

I have been unusually lucky in one respect. For more than fifteen years, I have had the chance to watch modern drug development from almost every angle: from early academic ideas and grant funding, through biotech bets and pharma portfolio decisions, to clinical trials, regulators, reimbursement, physicians, patient access and, finally, whatever makes it onto the pharmacy shelf.

Very few people get to stay in one field long enough to watch the whole machinery turn. I did, mostly by accident, and with enough distance from each individual part to notice how differently the same story looks depending on where you stand.

That does not mean I have all the answers. Quite the opposite. The longer you watch the system, the harder it becomes to believe in simple ones.

There is no Evil Corp running the whole show. There are scientists, executives, investors, regulators, insurers, doctors, journalists, advocates and patients, all making decisions inside their own constraints, all responding to their own incentives, and all convinced, usually with good reason, that they are doing the sensible thing.

Nobody has to behave monstrously for a system to produce monstrous inefficiency. Everyone can simply do their job.

That is the uncomfortable part. And probably the place to begin.